Oxagesic

Quick links to important sections

Oxagesic

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Oxagesic

Quick Facts

Property Description
Active Ingredients Acetaminophen (Paracetamol) and Diclofenac
Primary Form Film-coated tablets, Soft Gelatine Capsules
Pharmacological Class Analgesic, Anti-inflammatory (NSAID), Antipirético
Type Fixed-dose combination (FDC)
Origin Synthetic

What Type of Medicine is Oxagesic?

Oxagesic is classified as a fixed-dose combination (FDC) medicinal product, a formulation that contains two distinct active ingredients in a single unit. It is a synthetic drug that belongs to the high-level pharmacological classes of Analgesic (pain reliever), Anti-inflammatory (NSAID), and Antipirético (fever reducer). The medication is typically administered via the oral route as Film-coated tablets or Soft Gelatine Capsules, though parenteral forms for injection are formulated for acute clinical use.

Composition and The Dual-Action Principle

The core components of Oxagesic are the non-opioid pain reliever Acetaminophen (or Paracetamol) and Diclofenac, which is a phenylacetic acid derivative. This combination is strategically designed for comprehensive relief through a dual-action principle. Diclofenac functions as a Non-steroidal Anti-inflammatory Drug, while Acetaminophen contributes a strong analgesic effect. This specific pairing is designed to address various pain states through the co-administration of these two agents.

General Purpose: Treating Pain and Inflammation

The general therapeutic purpose of Oxagesic is to address moderate to severe discomfort in clinical situations where both acute pain and localized inflammation are contributing factors. The synergistic action achieved by combining an NSAID with a pure analgesic ensures the medicine targets pain pathways centrally while simultaneously reducing peripheral inflammation. This primary feature provides comprehensive coverage, making it a distinct option for those seeking a single product that addresses both pain and inflammation effectively.

Regulatory References

  1. NIH Clinical Studies

What side effects are possible with Oxagesic?

Possible Side Effects and Safety Information

The official safety information for Oxagesic is structured around identifying serious, potentially life-threatening risks, along with classifying common and less severe adverse reactions.


Serious and Clinically Significant Risks

Government regulatory documents include prominent warnings regarding the potential for serious adverse events, which can be fatal. These risks include:

  • Serious Cardiovascular Thrombotic Events: An increased risk of heart attack (myocardial infarction) and stroke has been documented, which may occur early in treatment and can increase with the duration of use and higher doses.
  • Serious Gastrointestinal Events: This includes life-threatening outcomes such as bleeding, ulceration, and perforation of the stomach or intestines. The risk is dose-dependent and can occur without prior warning symptoms.
  • Hepatotoxicity: Liver injury, including severe and sometimes fatal liver failure, has been reported.
  • Serious Skin Reactions: Severe hypersensitivity reactions such as Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) and severe blistering conditions (e.g., Toxic Epidermal Necrolysis) are rare but documented risks.

Common Adverse Reactions

Adverse reactions classified as Common in regulatory documents often involve the gastrointestinal system and include abdominal pain, nausea, diarrhea, and indigestion (dyspepsia). Nervous system effects such as headache and dizziness are also commonly reported.

Population-Specific Safety Considerations

Use of this medicine is contraindicated for the treatment of peri-operative pain immediately following coronary artery bypass graft (CABG) surgery. It is also advised that the drug be avoided from approximately 20 weeks gestation onward in pregnancy, as its use can cause fetal renal dysfunction leading to low amniotic fluid, and premature closure of the fetal ductus arteriosus after 30 weeks.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory documents define Oxagesic overdose primarily by its effects on the central nervous system and the respiratory system. Overdose is considered a serious medical emergency that can lead to death.

Clinical Manifestations of Overdose

Symptoms of a serious overdose or toxicity reflect severe central nervous system depression and may include:

  • Respiratory Depression: Slowed, shallow, or difficult breathing.
  • Severe Sedation: Extreme sleepiness (somnolence).
  • Unresponsiveness: Inability to wake up or respond to stimuli.

Factors Increasing Overdose Risk

Overdose risk is significantly increased by higher doses of opioid pain medicine. Furthermore, combining Oxagesic with other Central Nervous System (CNS) depressants, such as benzodiazepines, alcohol, or other sedating medicines, substantially elevates the risk of life-threatening respiratory depression, even when the medication is taken at prescribed doses.

When to Seek Emergency Medical Help

Immediate emergency medical help or calling 911 (or equivalent local emergency number) is required immediately if any symptoms of severe overdose are observed. Because overdose can be fatal, immediate action is essential. Patients and caregivers should discuss access to and instruction on the use of naloxone or nalmefene, which are opioid overdose reversal agents, as part of the overall risk management plan.

Therapeutic Uses of Oxagesic

Oxagesic is commonly used in situations involving certain distressing symptoms where both pain and inflammation are contributing factors, and is applied to offer symptomatic support. It is considered relevant in conditions characterized by periods of heightened symptoms.

The medication helps address symptom clusters that may become intense or disruptive, including persistent joint discomfort and stiffness in conditions like rheumatoid arthritis and osteoarthritis. It is applied in scenarios where additional management of discomfort is required following acute events such as dental surgery, soft tissue trauma, or to ease episodic pain from migraines and menstrual cramps.

“The medication may support the patient during difficult episodes by easing distress and contributing to improved comfort during symptomatic periods.”

This supportive relief may assist with maintaining functional stability and managing symptoms related to systemic imbalance, such as fever, when it accompanies pain.

Quick Fact: Symptom Management
Key Symptom Axes Musculoskeletal pain, acute localized swelling, episodic discomfort, systemic fever.
Therapeutic Benefit Supports easing overall symptom burden during periods of heightened physical discomfort.
Common Scenarios Used after procedures (e.g., dental), or for flares of chronic joint conditions.

Regulatory References

  1. Diclofenac: MedlinePlus Drug Information

Eligibility and Restrictions for Use

Oxagesic is primarily authorized for use in adults and adolescents 15 years of age and older. The official regulatory labeling strictly defines several populations who must not use this fixed-dose combination.

Use is contraindicated for patients with a known hypersensitivity to Acetaminophen, Diclofenac, or any other NSAIDs, including those with a history of aspirin-sensitive asthma. Absolute non-eligibility also applies to patients with active peptic ulcers or gastrointestinal bleeding and those with established severe heart failure (NYHA Class II-IV), ischaemic heart disease, peripheral arterial disease, or cerebrovascular disease. Furthermore, it is contraindicated in the setting of Coronary Artery Bypass Graft (CABG) surgery, severe hepatic insufficiency, severe renal insufficiency, and throughout the third trimester of pregnancy.

Use is restricted or requires caution in specific populations. Children less than 15 years of age are contraindicated in some regions. Older adults should use the medicine with caution due to increased susceptibility to effects on the liver and kidneys. Women who are breastfeeding or attempting to conceive are generally not recommended to use the medicine based on regulatory labeling.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define the Oxagesic interaction profile based on two active ingredients, resulting in established restrictions and required precautions with co-administered substances. Co-administration is formally prohibited with other Acetaminophen-containing products due to the risk of exceeding the total daily dose, which can lead to severe liver damage and acute liver failure. Concurrent use with other oral Nonsteroidal Anti-inflammatory Drugs (NSAIDs) must also be avoided as this significantly increases the risk of serious gastrointestinal events.


Documented Pharmacological Interactions

Interacting Agent Official Regulatory Statement
Anticoagulants (Warfarin) Requires careful monitoring due to the risk of amplified anticoagulant effect and increased risk of bleeding.
Lithium, Digoxin, Methotrexate Diclofenac co-administration can increase the serum concentrations of these agents, raising the risk of toxicity.
Antihypertensives, Diuretics Diclofenac may diminish the therapeutic effect of agents like ACE inhibitors, ARBs, and Furosemide, and may increase the risk of renal function deterioration.
Alcohol Risk of severe liver damage is formally documented if an individual consumes three or more alcoholic drinks daily while using the Acetaminophen component.

Population-Specific Notes: The regulatory information notes that the risk of serious renal function deterioration from interactions with antihypertensives is greater in elderly patients or those with pre-existing renal impairment. Cholestyramine requires a mandatory dose separation of at least one hour after taking the Acetaminophen component to ensure appropriate absorption.

Mechanism of Action

The fixed-dose combination of Acetaminophen and Diclofenac produces physiological changes through dual mechanistic domains that influence both peripheral tissue response and central signal transmission.

Enzyme-Mediated Pathway Modulation

This core mechanism involves the inhibition of Cyclooxygenase ( COX) enzymes by both active ingredients, reducing the synthesis of pro-inflammatory and pyretic mediators, notably Prostaglandin E2 ( PGE2). Diclofenac acts as a peripheral anti-inflammatory mechanism by preferentially inhibiting COX-2, thereby reducing the chemical sensitization of peripheral nociceptors and supporting the physiological normalization of the hypothalamic temperature set point.

Multi-Modal Central and Neuronal Signaling

Acetaminophen's activity is strongly central, relying on active metabolites to modulate pathways like the endocannabinoid CB1 system and descending serotonergic routes within the brain and spinal cord, influencing the physiological pain threshold. Complementarily, Diclofenac provides a direct analgesic mechanism by temporarily blocking Voltage-dependent Sodium ( Na^+) Channels, physically interrupting the flow of the pain signal along the nerve fiber. This concurrent action supports the modulation of multiple pathways involved in signal processing and transmission.

Dosage and Administration Information

The administration of Oxagesic is governed by its labeling, which defines the usage parameters for this oral fixed-dose combination (FDC) tablet or capsule. The route of administration is exclusively oral.


Administration Scope

The dosing regimen establishes a maximum intake limit of three tablets per 24 hours, which corresponds to a maximum daily exposure of 150 mg Diclofenac and 1500 mg Acetaminophen. Each dose, typically starting at one tablet, requires a mandatory separation interval of at least 6 to 8 hours.


Contextual Intake and Duration

Regarding procedural conditions, the labeling specifies that the dosage unit must be administered with or immediately following food or milk. To maintain the integrity of the combination's release profile, the tablet or capsule must be swallowed whole and is explicitly not authorized to be crushed, split, or chewed. Furthermore, the use of Oxagesic is designated as short-term only, typically limited to courses of 3 to 5 days for the management of acute symptomatic periods.


Population-Specific Rules

For certain populations, specific administration rules apply. For older adults (≥65 years), the instruction is to initiate treatment using the lowest effective dose for the shortest possible duration. Prescribing information also indicates that formal dose adjustments are required for patients with pre-existing hepatic impairment, which is detailed in the complete product documentation.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Oxagesic

Evidence for Use in Acute Pain Management

The research evidence for the fixed-dose combination of Diclofenac and Acetaminophen (Paracetamol) was evaluated in several contexts. A large body of research has explored the combination in acute, short-term discomfort, such as pain following procedures. These studies largely featured Randomized Controlled Trials (RCTs) that monitored adult patients experiencing moderate to severe pain.

Researchers examined outcomes related to physical discomfort. Findings describe patterns observed during the study period, with the combination being compared to its components taken alone. Some trials described patterns related to the recording of supplemental (rescue) pain medication among participants in the combination group during the immediate post-treatment period.

Research on Chronic Joint and Musculoskeletal Conditions

The combination was evaluated in research for conditions characterized by fluctuating or episodic manifestations like Osteoarthritis. These studies explored how symptoms evolved in the observed populations over intermediate-term follow-up periods, often tracking periods between 6 to 12 weeks. Comparative evidence is lacking from long-duration, direct RCTs for the specific fixed-dose combination in this chronic setting.

Long-Term Study Data and Follow-up

For the fixed-dose combination, there is limited information for long-term outcomes that track patients for extended durations, such as six months or longer. The existing research generally monitors responses over defined time intervals that rarely extend beyond three months. This means that the durability of symptom changes and how symptoms evolved in the observed populations over many months are not fully established. The limited information for long-term outcomes is acknowledged in the scientific literature for this specific fixed-dose pairing.

What is Still Uncertain About the Research

Several areas of uncertainty are acknowledged in the evidence base. Follow-up durations were limited across many key studies, meaning long-term effects are not fully established. Subgroup findings are also uncertain, as the main RCTs largely focused on narrowly defined adult populations, meaning data for certain groups (such as pediatric or pregnancy-related populations) remain insufficient. Research is ongoing to further characterize these areas of uncertainty.

Frequently Asked Questions (FAQ)

Common questions about Oxagesic (FAQ)


Q: How long does the primary effect of a standard dose of Oxagesic last?

Official information on how the body processes the medicine indicates that the time it takes for the concentration of the active components to decrease by half (known as the half-life) is generally between 1.5 to 3 hours. This measurement informs the required minimum dosing interval, which is 6 to 8 hours. The official labeling does not define the exact duration of symptom relief an individual may experience.


Q: Is Oxagesic ever approved for or prescribed to patients under the age of 18?

According to the official product information, this medicine is authorized for use in adults and adolescents 15 years of age and older. In some regions, its use is formally prohibited (contraindicated) for children under the age of 15.


Q: Can Oxagesic cause changes in sleep patterns or daytime drowsiness?

The official list of common side effects includes nervous system effects such as dizziness and headache. Less common effects documented in regulatory sources can include somnolence (drowsiness) or, conversely, insomnia.


Q: Is it okay to drink caffeine like coffee or tea while using Oxagesic?

Regulatory documents define specific, serious risks when combining this medicine with alcohol and certain other prescription drugs. Official warnings do not generally mention specific restrictions regarding the consumption of ordinary amounts of caffeine, such as coffee or tea.


Q: Are there any specific food types or ingredients that interact with Oxagesic?

The official prescribing information requires the dosage unit to be administered with or immediately following food or milk for procedural reasons. Beyond this general requirement, no specific food-drug interactions are documented in the regulatory labeling.


Q: Does Oxagesic lose its effectiveness if taken consistently for an extended period?

According to the official product information, this medicine is authorized only for short-term use, typically for courses of three to five days for acute periods of pain. The potential for the drug to lose its effectiveness (tolerance) is not addressed in the context of this short duration of authorized use.


Q: What happens if a dose of Oxagesic is missed?

Official patient instructions generally advise that a missed dose is typically skipped entirely. The recommendation is to take the next scheduled dose at the regular time, rather than attempting to double the dose to compensate for the one that was missed.


Q: Is Oxagesic prescribed for nerve pain or muscle spasms?

The approved purpose of the medicine is to address moderate to severe discomfort in clinical situations where both acute pain and localized inflammation are involved. The official labeling does not specify the exact origin of the pain, such as from the nerves or muscles.


Q: How is Oxagesic different from regular over-the-counter pain medication?

Oxagesic is defined as a fixed-dose combination medicine, meaning it contains two distinct active ingredients—an NSAID and an analgesic—in a single unit. This unique formulation is intended to provide a dual-action mechanism that addresses both pain signaling and peripheral inflammation for moderate to severe discomfort.


Q: Is Oxagesic a type of opioid or controlled substance?

The active ingredients in Oxagesic are officially classified as a Non-opioid Analgesic (Acetaminophen) and a Non-steroidal Anti-inflammatory Drug (NSAID) (Diclofenac). Whether the medicine is classified as a controlled or scheduled substance is determined by the local regulations of each government's drug agency.


Q: Do people commonly feel nauseous or have stomach upset when starting Oxagesic?

Nausea, abdominal pain, diarrhea, and indigestion are all listed in the regulatory documents as Common Adverse Reactions. Official information notes that these are frequently reported side effects but does not detail whether they are specific to the initial days of treatment.


Q: Does Oxagesic interact with any common over-the-counter cold or allergy medicines?

Regulatory documents formally prohibit co-administration with any other Acetaminophen-containing product and advise avoiding use with other oral Nonsteroidal Anti-inflammatory Drugs (NSAIDs). Many common over-the-counter cold, flu, or allergy medicines contain these ingredients, which creates a risk for drug overlap.


Q: How fast does Oxagesic typically start to provide pain relief?

According to pharmacokinetic studies, the time it takes for the concentration of the Diclofenac component to reach its maximum in the bloodstream is approximately 1.5 to 2 hours after administration. This information offers an indication of the expected timeframe for the onset of effect.


Q: Can the body build up a tolerance to Oxagesic over time?

Official regulatory documents authorize this drug for short-term use only. Because the drug is not intended or approved for long-term use, the issue of developing tolerance is not relevant within the scope of the current authorized labeling.


Q: What does it mean if Oxagesic carries a 'Black Box Warning' (if applicable)?

The content of a Black Box Warning, the FDA's most serious safety alert, is present in regulatory documents for the NSAID component. This warning prominently highlights the potential for Serious Cardiovascular Thrombotic Events (such as heart attack and stroke) and Serious Gastrointestinal Events (such as bleeding or ulceration).


Q: Is it possible to become dependent on Oxagesic based on official reports?

Regulatory information classifies the active ingredients as non-opioid and does not typically include documentation on abuse or dependence potential. This is consistent with the standard regulatory profile for this class of non-opioid pain reliever and anti-inflammatory drugs.

How should Oxagesic be stored and disposed of?

How to Store and Dispose of Oxagesic

Official regulatory guidelines strictly define how Oxagesic, a combination product of Acetaminophen and Diclofenac, must be stored and discarded.

Storage Conditions

The medication must be stored at room temperature, typically 15 C to 30 C (59 F to 86 F), and protected from light and moisture. It must be kept in its original container, tightly closed, and out of the sight and reach of children to prevent accidental ingestion. Storage environments that expose the medication to excessive heat or freezing must be avoided.

Disposal Instructions

Unused or expired Oxagesic should be disposed of via an authorized community drug take-back program. As an alternative, the medicine should be removed from its container, mixed with an undesirable substance like coffee grounds, placed in a sealed bag, and thrown into the household trash. The medication must not be flushed down the toilet or sink unless specific instructions on the labeling state otherwise.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Oxagesic found in:

A-Z Index: